Literature DB >> 6678874

The treatment of acute leukemia with continuous infusion L-Alanosine.

J K Weick, B L Tranum, F S Morrison.   

Abstract

L-Alanosine, an antitumor antibiotic was administered by members of the Southwest Oncology Group (SWOG) to 22 patients with resistant acute non-lymphocytic leukemia. The drug was administered by continuous infusion for five days at a starting dose of 125 mg/m2/day. Mucositis was dose-limiting in 15 patients and no marrow aplasia was attained. As administered, L-Alanosine is not an effective single agent in acute leukemia.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6678874     DOI： 10.1007/bf00208898

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  4 in total

1.  Phase I study of L-alanosine (NSC 15353).

Authors:  M A Goldsmith; T Ohnuma; M Spigelman; E M Greenspan; J F Holland
Journal:  Cancer       Date:  1983-02-01       Impact factor: 6.860

2.  Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate.

Authors:  J C Graff; P G Plagemann
Journal:  Cancer Res       Date:  1976-04       Impact factor: 12.701

3.  Alanosine, a new antiviral and antitumour agent isolated from a Streptomyces.

Authors:  Y K Murthy; J E Thiemann; C Coronelli; P Sensi
Journal:  Nature       Date:  1966-09-10       Impact factor: 49.962

4.  Phase I study of L-alanosine using a daily x 3 schedule.

Authors:  G M Dosik; D Stewart; M Valdivieso; M A Burgess; G P Bodey
Journal:  Cancer Treat Rep       Date:  1982-01
  4 in total
  1 in total

1.  Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.

Authors:  D D Von Hoff; S J Green; J A Neidhart; C Fabian; T Budd; J F Boyd; C K Osborne
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.